Eli Lilly and rival Novo Nordisk have been battling the emerging industry making copies of their top-selling diabetes and weight-loss drugs, a situation without modern precedent. It started in ...

Eli Lilly said it has begun selling vials of the smallest, starter dose of its popular weight-loss drug Zepbound in the United States for $399 for a month on its direct-to-consumer website to ...

Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...

In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...

As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up ...

Eli Lilly said it has started selling single-dose vials of its uber-popular weight-loss drug Zepbound as demand soars – and the smaller doses cost 50% less than rival drugs. The more affordable ...

Drugmaker Eli Lilly said Tuesday it will sell single-use vials of its weight-loss drug Zepbound at a fraction of the price of its pens, amid skyrocketing demand among Americans for anti-obesity ...

Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring ...

Eli Lilly's experimental next generation weight-loss drug mimics three hormones instead of just one or two and continues to ...

“I am gobsmacked that Lilly is seeking confidential patient medical records to build a case against the very therapies that ...

Indianapolis pharmaceutical giant Eli Lilly and Co. is asking people who took copies of its blockbuster weight loss drug to ...

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...